On a population-based level, the incidence of reactive arthritis (ReA) is 0.6-27/100,000. The definition of ReA varies and its pathogenesis is not yet clear. Attempts in basic immunology to suggest hypotheses for proliferation of forbidden B cell clones, molecular mimicry and involvement of cross-reactive antibodies are helpful but not sufficient. Importantly, for the clinical diagnosis of the preceding infection, serology is widely used. Unfortunately, the accuracy of associations between serologic findings and clinical conclusions is plagued by poor standardisation of methods. So far, few attempts have been done to examine the pitfalls of different approaches. Here, we review several serologic techniques, their performance and limitations. We will focus only on serology for Yersinia, Campylobacter, Salmonella and Chlamydia trachomatis because these bacteria have a longer history of being associated with ReA. We also address controversies regarding the role of serology for some other bacteria linked to autoimmune disorders.
Two commercial interferon gamma release assays (IGRAs) (QuantiFERON®-TB Gold in Tube and T SPOT®-TB) to detect a contact with M. tuberculosis have recently become available. The majority of studies agree that the sensitivity and specificity of these methods are superior to the Tuberculin Skin Tests (TSTs) in detecting an exposure to bacteria in latently infected individuals and in clinical tuberculosis. However, the data in children remains limited.
In 1872, in British Medical Journal (BMJ) Dr. David Ferrier published that Sarcina ventriculi (Goodsir) constantly occurred in the blood of man and the lower animals. His observation was based on bleeding experiments, incubation of blood at 100oF (37.8oC) and later examination. He found “immense numbers of beautifully formed sarcinæ”. In the next issue of BMJ Dr. Charlton Bastian expressed concerns that Sarcina might indeed be “really a living thing” or “might be partly organic and partly mineral in its constitutions”.
12 June 2007 in European Journal of Clinical Microbiology & Infectious Diseases
The performance of the interferon gamma release assays (IGRAs) and tuberculin skin test (TST) was reviewed retrospectively in patients with psoriasis, inflammatory musculoskeletal diseases, or miscellaneous inflammatory conditions. The study was carried out over a 22-month period using 109 records of patients with psoriasis (), musculoskeletal disease (), or other inflammatory conditions (). Forty-four (48%) of 109 patients were on immunosuppressive therapy and 38/109 (35%) on systemic glucocorticoid therapy. The agreement between the IGRAs was substantial () whilst that between the IGRAs and TST was low (). Logistic regression models revealed that IGRAs associated with risk factors for latent tuberculosis infection better than TST. TST was influenced by age, BCG vaccination, sex, and glucocorticoid therapy. We found that IGRAs performed equally well with low level of indeterminate results (1-2%). IGRAs were superior to TST because the latter was influenced by BCG-vaccination status and immunosuppressive therapy.
The presence of toxic indoor molds with accompanying bacterial growth is clearly detrimental to 16 human health. The pathophysiological and toxicological effects of toxins and structural 17 components of molds and bacteria have been clarified in experiments conducted in tissue culture 18 and animals and there is convincing epidemiologic evidence; nonetheless their implications for 19 human health are either ignored or denied, at least in Finland. In this communication, we 20 describe two cohorts suffering severe sequelae to mold-related illness. One cohort is a 9-member 21 family with pets that moved into a new house which soon proved to be infested with pathogenic 22 molds. The other cohort consists of 30 teachers and 50 students from a mold-infested school 23 building. The first cohort experienced a plethora of mucosal irritation, neurological, skin, allergic 24 and other symptoms, with all family members ultimately developing a multiple chemical 25 syndrome. In the second cohort, we detected a greatly elevated prevalence of autoimmune 26 conditions and malignancies. We claim that mold-related illness exists in multiple facets; it not 27 simply a transient mucosal irritation or even an increased risk of asthma onset or its 28 exacerbation. We propose a scheme to explain the natural course of the mold-related illness. We 29 recommend that future studies should combine data from e.g. cancer, autoimmune, endocrine 30 disorder registers, with mold-exposed individuals being monitored for prolonged follow-up 31 times.